Evofem Biosciences Inc

For the period ended Mar 31, 2025. Filed May 15, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 15, 2025

EVFM$0.48-23.4%Stored close · as of Aug 10, 2022

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

	Three Months Ended March 31,
	2025	2024
Product sales, net	$845	$3,603
Operating Expenses (Benefits):
Cost of goods sold	365	684
Amortization of intangible asset	223	-
Research and development, net	(5,035)	594
Selling and marketing	2,600	2,345
General and administrative	2,365	2,824
Total operating expenses	518	6,447
Income (loss) from operations	327	(2,844)
Other income (expense):
Interest income	8	4
Other expense, net	(600)	(616)
Loss on issuance of financial instruments	-	(3,275)
Gain on debt extinguishment, net	-	1,120
Change in fair value of financial instruments	1,221	802
Total other income (expense), net	629	(1,965)
Income (loss) before income tax	956	(4,809)
Income tax expense	-	-
Net income (loss)	956	(4,809)
Convertible and redeemable preferred stock deemed dividends	(3)	(47)
Net income (loss) attributable to common stockholders	$953	$(4,856)
Net income (loss) per share attributable to common stockholders:
Basic	$0.01	$(0.16)
Diluted	$0.00	$(0.16)
Weighted-average shares used to compute net income (loss) per share attributable to common shareholders:
Basic	113,356,354	31,194,393
Diluted	6,039,898,041	31,194,393

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.